Assessment of Five Screening Strategies for Optimal Detection of Carriers of Third-generation Cephalosporin-resistant Enterobacteriaceae in Intensive Care Units Using Daily Sampling
Overview
Authors
Affiliations
There is no consensus on optimal screening procedures for multidrug-resistant Enterobacteriaceae (MDRE) in intensive care units (ICUs). Therefore, we assessed five strategies for the detection of extended-spectrum beta-lactamase (ESBL) and high-level expressed AmpC cephalosporinase (HL-CASE) producers. During a 3-month period, a rectal screening swab sample was collected daily from every ICU patient, from the first 24 h to the last day of ICU stay. Samples were plated on MDRE-selective media. Bacteria were identified using MALDI-TOF mass spectrometry and antibiograms were performed using disk diffusion. MDREs were isolated from 682/2348 (29.0%) screening samples collected from 93/269 (34.6%) patients. Incidences of patients with ESBL and HL-CASE producers were 17.8 and 19.3 per 100 admissions, respectively. In 48/93 patients, MDRE carriage was intermittent. Compared with systematic screening at admission, systematic screening at discharge did not significantly increase the rate of MDRE detection among the 93 patients (62% vs. 70%). In contrast, screening at admission and discharge, screening at admission and weekly thereafter, and screening at admission and weekly thereafter and at discharge significantly increased MDRE detection (77%, p 0.02; 76%, p 0.01; 86%, p<0.001, respectively). The difference in MDRE detection between these strategies relies essentially on the levels of detection of patients with HL-CASE producers. The most reasonable strategy would be to collect two samples, one at admission and one at discharge, which would detect 87.5% of the ESBL strains, 67.3% of the HL-CASE strains and 77.4% of all MDRE strains. This study should facilitate decision-making concerning the most suitable screening policy for MDRE detection in a given ICU setting.
Heath M, Fan W, Leu C, Gomez-Simmonds A, Lodise T, Freedberg D Crit Care. 2024; 28(1):211.
PMID: 38943133 PMC: 11214232. DOI: 10.1186/s13054-024-04999-9.
Shamalov L, Heath M, Lynch E, Green D, Gomez-Simmonds A, Freedberg D Gut Pathog. 2024; 16(1):10.
PMID: 38383457 PMC: 10880254. DOI: 10.1186/s13099-024-00605-z.
Manquat E, Le Dorze M, Pean de Ponfilly G, Benmansour H, Amarsy R, Cambau E Ann Intensive Care. 2020; 10(1):149.
PMID: 33119840 PMC: 7594978. DOI: 10.1186/s13613-020-00754-9.
Andremont O, Armand-Lefevre L, Dupuis C, de Montmollin E, Ruckly S, Lucet J Intensive Care Med. 2020; 46(6):1232-1242.
PMID: 32313993 PMC: 7222166. DOI: 10.1007/s00134-020-06029-y.
Bonneault M, Andrianoelina V, Herindrainy P, Rabenandrasana M, Garin B, Breurec S Am J Trop Med Hyg. 2019; 100(6):1355-1362.
PMID: 31017082 PMC: 6553893. DOI: 10.4269/ajtmh.18-0410.